A detailed history of China Universal Asset Management Co., Ltd. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 8,872 shares of PCRX stock, worth $172,737. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,872
Previous 5,468 62.25%
Holding current value
$172,737
Previous $156,000 14.74%
% of portfolio
0.01%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$11.7 - $28.46 $39,826 - $96,877
3,404 Added 62.25%
8,872 $133,000
Q2 2024

Jul 19, 2024

SELL
$25.5 - $31.51 $88,281 - $109,087
-3,462 Reduced 38.77%
5,468 $156,000
Q1 2024

Apr 29, 2024

BUY
$27.7 - $35.48 $98,528 - $126,202
3,557 Added 66.2%
8,930 $261,000
Q4 2023

May 21, 2024

SELL
$26.32 - $34.31 $93,620 - $122,040
-3,557 Reduced 39.83%
5,373 $181,000
Q4 2023

Jan 23, 2024

BUY
$26.32 - $34.31 $110,228 - $143,690
4,188 Added 353.42%
5,373 $181,000
Q3 2023

May 21, 2024

BUY
$30.68 - $40.09 $17,886 - $23,372
583 Added 96.84%
1,185 $36,000
Q3 2023

Oct 30, 2023

BUY
$30.68 - $40.09 $17,886 - $23,372
583 Added 96.84%
1,185 $36,000
Q2 2023

May 21, 2024

SELL
$36.12 - $47.5 $758 - $997
-21 Reduced 3.37%
602 $24,000
Q2 2023

Jul 27, 2023

SELL
$36.12 - $47.5 $758 - $997
-21 Reduced 3.37%
602 $24,000
Q1 2023

May 21, 2024

BUY
$35.53 - $43.38 $5,578 - $6,810
157 Added 33.69%
623 $25,000
Q1 2023

Apr 27, 2023

BUY
$35.53 - $43.38 $5,578 - $6,810
157 Added 33.69%
623 $25,000
Q4 2022

May 21, 2024

SELL
$38.19 - $57.45 $323,240 - $486,256
-8,464 Reduced 94.78%
466 $17,000
Q4 2022

Jan 31, 2023

BUY
$38.19 - $57.45 $1,413 - $2,125
37 Added 8.62%
466 $18,000
Q3 2022

Oct 21, 2022

BUY
$51.24 - $58.89 $21,981 - $25,263
429 New
429 $23,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.